CN111437248A - Intestine-benefiting life-prolonging oral liquid and preparation method and application thereof - Google Patents
Intestine-benefiting life-prolonging oral liquid and preparation method and application thereof Download PDFInfo
- Publication number
- CN111437248A CN111437248A CN202010187906.4A CN202010187906A CN111437248A CN 111437248 A CN111437248 A CN 111437248A CN 202010187906 A CN202010187906 A CN 202010187906A CN 111437248 A CN111437248 A CN 111437248A
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- intestine
- benefiting
- life
- prolonging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 83
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 230000009286 beneficial effect Effects 0.000 claims abstract description 9
- 230000001954 sterilising effect Effects 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 229920001661 Chitosan Polymers 0.000 claims description 15
- 229920000858 Cyclodextrin Polymers 0.000 claims description 15
- 239000001116 FEMA 4028 Substances 0.000 claims description 15
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 15
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 15
- 229960004853 betadex Drugs 0.000 claims description 15
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 15
- 238000004659 sterilization and disinfection Methods 0.000 claims description 15
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 13
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 13
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 13
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 13
- 239000011550 stock solution Substances 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 210000000936 intestine Anatomy 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 244000197580 Poria cocos Species 0.000 claims description 9
- 235000008599 Poria cocos Nutrition 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 229940045110 chitosan Drugs 0.000 claims description 7
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 244000062995 Cassia occidentalis Species 0.000 claims description 5
- 235000001948 Cassia occidentalis Nutrition 0.000 claims description 5
- 244000183685 Citrus aurantium Species 0.000 claims description 5
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 5
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 5
- 244000088415 Raphanus sativus Species 0.000 claims description 5
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 5
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 244000170916 Paeonia officinalis Species 0.000 claims 2
- 235000013365 dairy product Nutrition 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 abstract description 42
- 230000000968 intestinal effect Effects 0.000 abstract description 26
- 229910052793 cadmium Inorganic materials 0.000 abstract description 25
- 241000186000 Bifidobacterium Species 0.000 abstract description 20
- 239000006041 probiotic Substances 0.000 abstract description 20
- 235000018291 probiotics Nutrition 0.000 abstract description 20
- 241000186660 Lactobacillus Species 0.000 abstract description 19
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 19
- 229940039696 lactobacillus Drugs 0.000 abstract description 17
- 230000036039 immunity Effects 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 6
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- 230000004962 physiological condition Effects 0.000 abstract description 3
- 230000002062 proliferating effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 44
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 10
- 206010027439 Metal poisoning Diseases 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 230000029142 excretion Effects 0.000 description 9
- 230000000529 probiotic effect Effects 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 230000008859 change Effects 0.000 description 7
- 208000008127 lead poisoning Diseases 0.000 description 7
- 208000005882 cadmium poisoning Diseases 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 229910052745 lead Inorganic materials 0.000 description 6
- 230000000607 poisoning effect Effects 0.000 description 6
- 241000186604 Lactobacillus reuteri Species 0.000 description 5
- 208000005374 Poisoning Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229940001882 lactobacillus reuteri Drugs 0.000 description 5
- 231100000572 poisoning Toxicity 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002224 dissection Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000009931 harmful effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000000779 smoke Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241001106477 Paeoniaceae Species 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 241000405414 Rehmannia Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000005485 electric heating Methods 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940095399 enema Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 208000010501 heavy metal poisoning Diseases 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 229940046892 lead acetate Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 2
- -1 polytetrafluoroethylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010061762 Chondropathy Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 206010034156 Pathological fracture Diseases 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000002389 Pouchitis Diseases 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000007373 microbial translocation Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C2240/00—Use or particular additives or ingredients
- A23C2240/15—Use of plant extracts, including purified and isolated derivatives thereof, as ingredient in dairy products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The application discloses intestine-benefiting life oral liquid and a preparation method and application thereof, and the prepared intestine-benefiting life oral liquid is suitable for middle-aged and elderly people in a sub-health state. The intestine-benefiting life-prolonging oral liquid has double functions, and on one hand, the intestinal-benefiting life-prolonging oral liquid can promote discharge of heavy metals such as cadmium, lead and the like accumulated in an organism and reduce the toxicity of the heavy metals to the organism; on the other hand, the lactobacillus and bifidobacterium which are intestinal probiotics have obvious proliferation effect, and are beneficial to middle-aged and elderly people in sub-health state to enhance the immunity of the organism and improve the physiological condition of the organism by proliferating the intestinal probiotics. The intestine-benefiting life-prolonging oral liquid is low in cost, free of toxic and side effects and capable of being widely popularized and used.
Description
Technical Field
The application relates to the technical field of heavy metal excretion promotion, in particular to intestine-benefiting life-prolonging oral liquid and a preparation method and application thereof.
Background
Along with the industrial development of China, the environmental pollution caused by industrial three wastes is increasingly serious, and particularly the heavy metal pollution can cause great harm to the whole biological chain and an ecological system. Some toxic and harmful substances such as heavy metals of cadmium, lead and the like can migrate to water and soil and enter human bodies through food chains, so that the toxic and harmful substances bring accumulative harm to human health; in addition, heavy metals can also enter the human body through the respiratory tract through particles (PM 2.5) in haze and dust.
Although China requires that the industrial three wastes must be purified and discharged after reaching standards, the pollution of the three wastes is still severe. According to statistics, the cadmium released to the environment every year in the world reaches about 3 million tons, wherein 82% -94% of the cadmium can enter the soil, and the cadmium in the soil enters the human body or the livestock body through water, crops or fishes and shrimps and can be accumulated in the internal organs of the human body or the livestock through the biological enrichment effect, so that the serious damage is caused to the organs and tissues such as the kidney, the bones and the like. For example, in the 60 th 19 th century, "osteodynia" occurred in japan, namely cadmium (cadmium, Cd) entered the human body through the food chain, cadmium is highly toxic, air and food contaminated with cadmium are seriously harmful to the human body, and is slowly metabolized in the human body, i.e., the body accumulates excessive cadmium to deteriorate the function of the renal tubule, causing the loss of protein from urine in the body, and the more the body accumulates at a higher age, and in addition, cadmium can replace calcium in the body to form chondropathy and spontaneous fracture over time.
Lead (Plumbum, Pb) poisoning is not only frequently caused in children, but also serious in injury to adults, and causes diseases such as nervous system, digestive system, blood system, cardiovascular system, renal function damage, reproductive system damage and the like, and is increasingly attracting social attention.
At present, the attention on the content of heavy metals in a human body is less, and related treatment work is generally carried out only when the human body has a heavy metal poisoning symptom, at the moment, the content of heavy metals in the human body is more and seriously exceeded, the human body is damaged, and more damages are irreversible. Therefore, in order to reduce the damage of heavy metals to the human body, the heavy metals should be prevented from being accumulated in the human body for a long time, especially for middle-aged and elderly people in sub-health state, the heavy metals entering the human body are regularly discharged, the heavy metal content of the human body is controlled within a standard range, and the heavy metal poisoning problem of the human body is avoided.
However, no heavy metal excretion promoting product which is suitable for middle-aged and elderly people in sub-health state and can promote excretion of various heavy metals is available in the market. Therefore, a heavy metal detoxification medicament which is suitable for middle-aged and elderly people in a sub-health state and can promote the discharge of multiple heavy metals simultaneously is urgently needed.
Disclosure of Invention
The application provides intestine-benefiting life-prolonging oral liquid and a preparation method and application thereof, and aims to solve the problem that no heavy metal excretion promoting product which is suitable for middle-aged and elderly people in a sub-health state and can promote excretion of various heavy metals is available in the market at present.
In a first aspect, the application provides an intestine-benefiting and life-prolonging oral liquid, which comprises effective components, auxiliary material components and a solvent, wherein the effective components comprise carboxymethyl chitosan, β -cyclodextrin, fructo-oligosaccharide and stachyose, the auxiliary material components comprise radix paeoniae alba, fructus aurantii, radix rehmanniae, semen cassiae torae, poria cocos and semen raphani, and the solvent is water.
Optionally, the mass ratio of carboxymethyl chitosan, β -cyclodextrin, fructo-oligosaccharide and stachyose is 1:1:2:1, and the mass ratio of radix Paeoniae alba, fructus Aurantii, radix rehmanniae, semen Cassiae, Poria and Raphani semen is 1:1: 1.5: 1.5: 1.5: 2.
Optionally, the effective components comprise 5g of carboxymethyl chitosan, 5g of β -cyclodextrin, 10g of fructo-oligosaccharide and 5g of stachyose in parts by weight, and the auxiliary materials comprise 5g of radix paeoniae alba, 5g of fructus aurantii, 7.5g of radix rehmanniae, 7.5g of semen cassiae torae, 7.5g of poria cocos and 10g of semen raphani in parts by weight.
Alternatively, the amount of solvent is 200-300 ml.
In a second aspect, the application also provides a method for preparing the intestine-benefiting and life-prolonging oral liquid, which comprises the processes of crushing and mixing auxiliary materials, preparing liquid medicine, introducing effective ingredients, controlling viscosity and sterilizing.
Wherein, the auxiliary material is smashed and is specifically included with the mixing process: pulverizing radix Paeoniae alba, fructus Aurantii, radix rehmanniae, semen Cassiae, Poria and Raphani semen, and mixing in a mixer to obtain mixed adjuvants;
the liquid medicine preparation process specifically comprises the following steps: adding appropriate amount of water into the mixed adjuvants, decocting at 80-95 deg.C for about 1 hr, filtering to remove residue, and collecting the upper layer medicinal liquid;
the step of introducing effective components comprises adding carboxymethyl chitosan, β -cyclodextrin, fructo-oligosaccharide and stachyose into the obtained medicinal liquid, stirring thoroughly until the effective components are dissolved in the medicinal liquid, and making into oral stock solution;
the viscosity control process specifically comprises the following steps: adjusting the viscosity of the oral stock solution to obtain oral liquid;
the sterilization process specifically comprises the following steps: sterilizing the oral liquid, wherein the sterilization time is 10-30 minutes, the sterilization temperature is 110-130 ℃, and the sterilization pressure is 1.0-1.2 kpa.
In a third aspect, the application also provides an application of the intestine-benefiting life oral liquid, and the intestine-benefiting life oral liquid is used as a beneficial additive component in a milk product or a health-care product for the middle-aged and elderly people.
The application provides intestine-benefiting life-prolonging oral liquid and a preparation method and application thereof, and the prepared intestine-benefiting life-prolonging oral liquid is suitable for middle-aged and elderly people in a sub-health state. The intestine-benefiting life-prolonging oral liquid has double functions, and on one hand, the intestine-benefiting life-prolonging oral liquid can adsorb and promote discharge of heavy metals such as cadmium, lead and the like, and reduce the toxicity of the heavy metals to organisms; on the other hand, the intestinal probiotic lactobacillus and bifidobacterium can be obviously proliferated by taking the intestinal probiotic oral liquid, and the intestinal probiotic lactobacillus and bifidobacterium are beneficial to the middle-aged and elderly people in a sub-health state to enhance the immunity of the organism and improve the physiological condition of the organism by proliferating the intestinal probiotic. In addition, the intestine-benefiting life-prolonging oral liquid is low in cost, free of toxic and side effects and capable of being widely popularized and used.
Drawings
In order to more clearly explain the technical solution of the present application, the drawings needed to be used in the embodiments will be briefly described below, and it is obvious to those skilled in the art that other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 is a flow chart of the preparation method of the oral liquid for benefiting intestine and longevity,
FIG. 2 is a Pb standard curve;
FIG. 3 is a Cd standard curve;
FIG. 4 is a graph of intrabody weight changes in four weeks for various groups of mice in a lead poisoning test;
FIG. 5 is a graph showing the change of intestinal flora in four weeks for each group of mice in a lead poisoning test;
FIG. 6 is a graph showing the change in lead content in the kidney over four weeks for each group of mice in the lead poisoning test;
FIG. 7 is a graph of intrabody weight changes in four weeks for various groups of mice in a cadmium poisoning test;
FIG. 8 is a graph showing the change of intestinal flora in four weeks for each group of mice in the cadmium poisoning test;
FIG. 9 is a graph showing the change in renal cadmium levels in four weeks for each group of mice in the cadmium poisoning test.
Detailed Description
The application provides an intestine-benefiting life-prolonging oral liquid which is suitable for middle-aged and elderly people in a sub-health state, can adsorb and promote discharge of heavy metals such as cadmium and lead, and can reduce toxicity of the heavy metals to organisms.
The intestine-benefiting and life-prolonging oral liquid comprises effective components, auxiliary material components and a solvent, wherein the effective components comprise carboxymethyl chitosan, β -cyclodextrin, fructo-oligosaccharide and stachyose, the auxiliary material components comprise white paeony root, bitter orange, radix rehmanniae, cassia occidentalis, poria cocos and radish seed, and the solvent is water.
In the effective components, the two health-care substances of carboxymethyl chitosan and β -cyclodextrin have the main functions of promoting the excretion of heavy metals in the body, enhancing the immunity of the organism and promoting the proliferation of probiotic lactobacillus in the intestinal tract, the lactobacillus is the normal dominant bacterium in the intestinal tract of the human body, is beneficial to the digestion and absorption of a host, can inhibit pathogenic bacteria, increase the number of lymphocytes in the intestinal tract and enhance the immunity of the organism, and the fructo-oligosaccharide and stachyose have the main effects of promoting the proliferation of probiotic bifidobacterium in the intestinal tract and enhancing the immunity of the organism.
Among the auxiliary components, the white peony root has the effects of regulating liver-spleen disharmony and headache dizziness; the bitter orange has better effects on indigestion of middle-aged and elderly people and abdominal fullness and pain; the rehmannia root has the main effects of clearing heat, relaxing bowels, protecting liver, resisting tumor and improving immunity; the cassia seed has the main effects of improving eyesight, benefiting gallbladder, protecting liver and relaxing bowel; the tuckahoe has the main effects of inducing diuresis to alleviate edema, excreting dampness, strengthening spleen and calming heart; the radish seed has better effects on people with food stagnation, qi stagnation, cough, asthma, excessive phlegm and chest distress and poor appetite.
In the example, the mass ratio of the carboxymethyl chitosan, the β -cyclodextrin, the fructo-oligosaccharide and the stachyose is 1:1:2:1, and the mass ratio of the white paeony root, the bitter orange, the dried rehmannia root, the cassia occidentalis, the poria cocos and the radish seed is 1:1: 1.5: 1.5: 1.5: 2.
In the embodiment, the active ingredients comprise the following raw materials, by weight, 5g of carboxymethyl chitosan, 5g of β -cyclodextrin, 10g of fructo-oligosaccharide and 5g of stachyose, and the auxiliary materials comprise the following raw materials, by weight, 5g of white paeony root, 5g of fructus aurantii, 7.5g of radix rehmanniae, 7.5g of cassia occidentalis, 7.5g of poria cocos and 10g of semen raphani.
In this example, the amount of the solvent is 200-300ml, and the amount of the solvent can be adjusted by those skilled in the art according to actual needs, for example, 250ml, which falls within the scope of the present application.
Fig. 1 is a flow chart of a preparation method of the intestine-benefiting life oral liquid, and as shown in fig. 1, the preparation method of the intestine-benefiting life oral liquid comprises the processes of crushing and mixing auxiliary materials, preparing liquid medicine, introducing effective components, controlling viscosity and sterilizing.
Wherein, step 100, the auxiliary material is smashed and is included with the mixing process specifically: pulverizing radix Paeoniae alba, fructus Aurantii, radix rehmanniae, semen Cassiae, Poria and Raphani semen, and mixing in a mixer to obtain mixed adjuvants;
in step 400, the viscosity control process specifically comprises adjusting the viscosity of the oral stock solution to obtain the oral solution, wherein the carboxymethyl chitosan and β -cyclodextrin have the characteristic of film formation, and after the carboxymethyl chitosan and β -cyclodextrin are added into the liquid medicine, the viscosity of the oral stock solution needs to be adjusted to prevent the excessive viscosity.
In this embodiment, the preparation method of the intestine-benefiting life oral liquid further includes placing the dried intestine-benefiting life oral liquid in a plastic packaging bottle meeting the hygienic food safety standard, and packaging.
The application also provides an application of the intestine-benefiting life oral liquid, and the intestine-benefiting life oral liquid is used as a beneficial additive component in a milk product or a health-care product for the middle-aged and the elderly. The intestine-nourishing and life-prolonging oral liquid is used as a beneficial component and can be added into milk products or middle-aged and elderly health products.
In order to verify the in vivo excretion promoting effect of the intestine-benefiting life-prolonging oral liquid on heavy metals such as cadmium, lead and the like, experiments are carried out by taking mice as experimental materials.
1. Establishment of heavy metal contaminated mouse model
1.1 enema intestine-benefiting longevity oral liquid
(1) Grouping
112 mice were randomly divided into 7 groups: one blank group, three intoxicated groups and three test groups of 16 mice each. The blank group is perfused with stomach physiological saline for 2 weeks, the poisoning group and the test group are separately perfused with stomach Pb and Cd solutions for 2 weeks, after each week, three groups are dissected for 4, and the poisoning effect of the three heavy metals is observed by mutual contrast among the three groups.
(2) Weighing and feeding
Mice were weighed beginning at 9 am each day and the body weight of each mouse was recorded. After weighing, feeding mice with grain according to the weight and the number of each group of mice (the feeding amount of each mouse is 2 g/mouse in the daytime and 3 g/mouse in the evening), and ensuring enough cold boiled water for the mice.
(3) Gavage stomach
The mice were gazed at 10 am. the mice were gazed with normal saline for the blank group, lead acetate 10 mg/L for the lead poisoning group and the test group, and 0.1 mg/L for the cadmium poisoning group and the test group, and injected at 1ml/10 g.
1.2 cultivation of intestinal flora
(1) Collection of faeces
Before the mice are injected into the abdominal cavity, the feces of each mouse are collected by means of abdominal massage and placed in a sterilized centrifugal tube, and marking is carried out. The collection frequency was 2 days.
(2) Fecal treatment
The collected feces were diluted 100-fold by weighing 0.1g in 9.9ml of water and immediately transferred to an ultra-clean bench for gradient dilution with a dilution gradient of 106.
(3) Culture of bacterial flora
Pouring four sterilized culture mediums on an ultra-clean workbench into four plates, turning on an ultraviolet lamp for 15 minutes, quickly coating and inoculating after the plates are cooled, marking, and standing for 10 minutes. Sealing two anaerobic bacteria culture dishes (lactobacillus and bifidobacterium) by using sealing strips, putting the two anaerobic bacteria culture dishes and all the culture dishes into a constant temperature incubator, and culturing for 48 hours at 37 ℃.
(4) Flora count
After 48 hours all dishes were removed, and the four bacterial populations of lactobacilli, bifidobacteria, escherichia coli, enterococci were counted and recorded.
1.3 determination of Pb and Cd contents
(1) Dissecting mice
The selected mice for dissection are separated independently, the mice are sacrificed one by adopting a neck-broken sacrifice method, and then are soaked in 75% alcohol for 5 minutes and transferred to an ultra-clean workbench for dissection. The kidney is taken out and put into a sterile packaging bag, and then is transferred to a refrigerator with the temperature of 20 ℃ below zero for storage.
(2) Digestion organ
Taking out mouse kidney organ, precisely weighing, placing in 50ml polytetrafluoroethylene crucible, adding nitric acid 10ml, covering, soaking overnight, placing the crucible on electric heating plate, digesting at 200 deg.C, and intermittently adding hydrogen peroxide until the yellow-brown smoke is converted into white smoke. And finally, adding about 10ml of water, continuously heating to drive acid, heating to be nearly dry, cooling, adding distilled water, transferring to a 50ml volumetric flask, diluting to a scale with the distilled water, and fixing the volume.
(3) Preparation of standard curve
1) Preparation of Pb standard solution
Weighing Pb single element stock solution 10m L of 0.1 mg/m L, carrying out constant volume by using a 100m L0 volumetric flask, shaking up to obtain standard stock solution of Pb with the concentration of 10 mug/m L1, taking five clean 50m L2 volumetric flasks after drying, respectively transferring standard stock solutions 1m L4, 2 m L5, 3 m L6, 4 m L7, 5 m L and 6 m L of 10 mug/m L3 Pb into the volumetric flasks by using a liquid transfer gun, respectively carrying out constant volume to a scale, shaking up to obtain standard sequence concentrations of Pb in the five volumetric flasks of 0.2 mug/m L, 0.4 mug/m L, 0.6 mug/m L, 0.8 mug/m L, 1.0 mug/m L and 1.2 mug/m L, respectively attaching a standard label to the standard sequence concentrations of Pb to obtain a standard curve shown in a Pb 2 graph.
2) Preparation of Cd standard solution
Measuring 2 m L of Cd single element stock solution with the concentration of 0.1 mg/m L, carrying out constant volume by using a 100m L0 volumetric flask, shaking up to obtain standard stock solution of Cd with the concentration of 2 mug/m L1, taking five clean 50m L2 volumetric flasks, respectively transferring 0.25 m L4, 1.25 m L5, 2.5 m L6, 5 m L7, 7.5 m L and 10m L of standard stock solution of 2 mug/m L3 Cd into the volumetric flasks by using a liquid transfer gun, respectively carrying out constant volume to scale, shaking up to obtain standard sequence concentrations of Cd in the five volumetric flasks of 0.01 mug/m L, 0.05 mug/m L, 0.1 mug/m L, 0.2 mug/m L, 0.3 mug/m L and 0.4 mug/m L, and respectively attaching standard labels with the concentrations as shown in a standard curve chart 3.
4) Data processing
And calculating the content of the heavy metal in the sample solution according to the standard curve of the concentration of each heavy metal. The kidneys were analyzed for heavy metal enrichment.
2. Intestine-benefiting longevity oral liquid for gastrectatic mice
2.1 enema, intestine-benefiting and longevity oral liquid
(1) Grouping
After the first two weeks of experiments, only 8 mice were left per group, and the total of 72 mice in the three groups. And then, infusing the stomach normal saline for 2 weeks in a blank group, infusing the stomach normal saline for 2 weeks in a poisoning group, infusing the stomach normal saline for 2 weeks in a test group, dissecting 4 of the three groups after each week is finished, and observing the detoxifying effect of the intestine-nourishing oral liquid through mutual contrast among the three groups.
(2) Weighing and feeding
Mice were weighed beginning at 9 am each day and the body weight of each mouse was recorded. After weighing, feeding mice with grain according to the weight and the number of each group of mice (the feeding amount of each mouse is 2 g/mouse in the daytime and 3 g/mouse in the evening), and ensuring enough cold boiled water for the mice.
(3) Gavage of mice
Gavage was started at 10 a.m. according to the weight of the mice on that day. The water solution of the oral liquid for gastric lavage and intestine benefiting is used for gastric lavage according to the amount of 0.1ml/10g in the blank group, the normal saline for gastric lavage in the poisoning group and the water solution of the oral liquid for gastric lavage and intestine benefiting in the test group.
2.2 cultivation of intestinal flora
(1) Collection of faeces
Before the mice are injected into the abdominal cavity, the feces of each mouse are collected by means of abdominal massage and placed in a sterilized centrifugal tube, and marking is carried out. The collection frequency was 2 days.
(2) Fecal treatment
The collected feces were diluted 100-fold by weighing 0.1g in 9.9ml of water and immediately transferred to an ultra-clean bench for gradient dilution with a dilution gradient of 106.
(3) Culture of bacterial flora
Pouring four sterilized culture mediums on an ultra-clean workbench into four plates, turning on an ultraviolet lamp for 15 minutes, quickly coating and inoculating after the plates are cooled, marking, and standing for 10 minutes. Two anaerobic culture dishes (lactobacillus and bifidobacterium) are sealed by a sealing strip, and are put into a constant temperature incubator together with all the culture dishes to be cultured for 48 hours under the condition of 37 OC.
(4) Flora count
After 48 hours all dishes were removed, and the four bacterial populations of lactobacilli, bifidobacteria, escherichia coli, enterococci were counted and recorded.
2.3 determination of Pb and Cd contents
(1) Dissecting mice
The selected mice for dissection are separated independently, the mice are sacrificed one by adopting a neck-broken sacrifice method, and then are soaked in 75% alcohol for 5 minutes and transferred to an ultra-clean workbench for dissection. The kidney is taken out and put into a sterile packaging bag, and then is transferred to a refrigerator with the temperature of 20 ℃ below zero for storage.
(2) Digestion organ
Taking out mouse kidney organ, precisely weighing, placing in 50ml polytetrafluoroethylene crucible, adding nitric acid 10ml, covering, soaking overnight, placing the crucible on electric heating plate, digesting at 200 deg.C, and intermittently adding hydrogen peroxide until the yellow-brown smoke is converted into white smoke. And finally, adding about 10ml of water, continuously heating to drive acid, heating to be nearly dry, cooling, adding distilled water, transferring to a 50ml volumetric flask, diluting to a scale with the distilled water, and fixing the volume.
(3) Data processing
And measuring the absorbance of three heavy metal samples, and calculating the content of the heavy metal in the sample solution according to the standard curve of the concentration of each heavy metal. The kidneys were analyzed for heavy metal enrichment.
3. Results of the study
3.1 lead poisoning in mice
(1) Weight change
As shown in fig. 4, the weight of the mice in the blank group was linearly increased, and the weight of the mice was decreased within the first week of lead poisoning by gastric gavage of lead acetate. The weight of the mice is wholly increased within four weeks, and compared with the poisoned group, the weight of the mice is recovered after the oral liquid for stomach irrigation, intestine nourishing and life prolonging.
(2) Changes in intestinal flora
As shown in fig. 5, after the oral liquid starts to be infused in the stomach and intestine, the probiotics lactobacillus and bifidobacterium in the intestinal tract obviously proliferate.
(3) Lead content in kidney
As shown in fig. 6, after lead poisoning, lead is mainly enriched in the kidney, and after the oral liquid for stomach irrigation, intestine nourishing and life prolonging, the lead content in the kidney is reduced.
3.2 cadmium poisoning in mice
(1) Weight change
As shown in FIG. 7, the body weight of the mice in the blank group increased linearly, while the body weight of the mice infused with the gastric cadmium solution decreased significantly within the first week. The weight of the mice is wholly raised within four weeks, and compared with the poisoning group, the oral liquid for reinforcing the stomach, benefiting the intestine and prolonging the life has a promoting effect on the weight recovery of the mice in the test group.
(2) Changes in intestinal tract number
As shown in fig. 8, after the oral liquid starts to be infused in the stomach and intestine, the probiotics lactobacillus and bifidobacterium in the intestinal tract obviously proliferate.
(3) Changes in renal cadmium content
As shown in FIG. 9, after cadmium poisoning, lead was distributed in the kidney, and the content of cadmium in the kidney was reduced after the oral liquid was administered.
In conclusion, from the change conditions of the weight and the appearance characteristics (such as fur and the like) of the mouse, the infection of Pb and Cd has a harmful effect on the mouse, and the mouse has obvious inappetence, listlessness and death of part of individuals; the kidney is measured for Pb and Cd contents, and the remarkable increase is found, but the intestinal flora is not remarkably changed. After the stomach-reinforcing intestine-benefiting life-prolonging oral liquid is infused to the infected mice, the infected mice are found to have the sign of recovering health from the aspects of weight and behavior, the Pb and Cd contents in the kidney tend to be reduced, and the quantity of lactobacillus and bifidobacterium in the intestinal tract is also increased.
4. Conclusion
According to the test results, the intestine-benefiting life-prolonging oral liquid has a certain positive effect on promoting discharge and detoxification of heavy metal contamination, and has the effect of promoting proliferation of intestinal probiotics including lactobacillus and bifidobacterium in the intestinal tract, and the specific effects include:
(1) the intestine-benefiting life oral liquid has strong heavy metal adsorption capacity, and has a good effect when being used for promoting the excretion of various heavy metals in an organism compared with other heavy metal excretion promoters, and meanwhile, the intestine-benefiting life oral liquid has small toxic and side effects due to good biocompatibility.
(2) On the other hand, the intestine-benefiting life-prolonging oral liquid can improve the composition of intestinal flora and promote the proliferation of intestinal probiotics, namely lactobacillus and bifidobacterium.
Among them, lactobacillus is an important group of intestinal probiotics, such as lactobacillus reuteri, which is commonly present in vertebrates, and has several beneficial effects, first, lactobacillus reuteri can produce antibacterial molecules, which can inhibit colonization by pathogenic microorganisms and remodel symbiotic microbiota; second, lactobacillus reuteri can benefit the host immune system; third, to strengthen the intestinal barrier, colonization by lactobacillus reuteri may reduce microbial translocation from the intestinal lumen to the tissue. Therefore, direct supplementation or prebiotic modulation of lactobacillus reuteri may be an effective way to prevent and treat inflammatory diseases.
Bifidobacteria (bifidobacteria) are important intestinal probiotics and have various probiotic functions, including improvement of intestinal diseases caused by immune system disorder, such as inflammatory bowel disease, ulcerative colitis, crohn's disease, pouchitis and the like; the antibacterial peptide is adhered to epithelial cells of the intestinal tract and secretes the antibacterial peptide, and meanwhile, the thickness of the mucus layer is increased, so that pathogenic bacteria are inhibited from invading the intestinal tract; scavenging free radicals, improving host antioxidase activity, and reducing serum and liver malondialdehyde content, thereby relieving oxidative damage of organism and delaying aging.
According to the research, the absolute dominance of bifidobacteria in the intestinal tract of infants is up to 99%, and that of healthy people (26-28 years old) is only 14.8%, while that of the elderly is only 3.2%. The probiotics such as bifidobacterium and lactobacillus are active microorganisms which are beneficial to a host and are formed by changing flora at a certain part of the host through colonization in a human body, promote digestion and absorption of food by regulating the immune function of the host mucous membrane and the system or regulating the flora balance in intestinal tracts, prevent constipation and synthesize vitamins, thereby enhancing the immunity of the human body and improving the antioxidation level of the organism.
The intestine-benefiting life-prolonging oral liquid can improve the composition of intestinal flora and promote the proliferation of intestinal probiotics, namely lactobacillus and bifidobacterium, and the proliferation of the intestinal probiotics can firstly maintain the stable state of the intestinal flora and secondly can act with heavy metals to reduce the toxicity of the heavy metals, thereby further reducing the damage of the heavy metals to human bodies.
The application provides intestine-benefiting life-prolonging oral liquid and a preparation method and application thereof, and the prepared intestine-benefiting life-prolonging oral liquid is suitable for middle-aged and elderly people in a sub-health state. The intestine-benefiting life-prolonging oral liquid has double functions, and on one hand, the intestine-benefiting life-prolonging oral liquid can adsorb and promote discharge of heavy metals such as cadmium, lead and the like, and reduce the toxicity of the heavy metals to organisms; on the other hand, the intestinal probiotic lactobacillus and bifidobacterium can be obviously proliferated by taking the intestinal probiotic lactobacillus and bifidobacterium, and can promote intestinal peristalsis, relieve constipation of middle-aged and elderly people, inhibit the formation of intestinal putrefactive substances, promote gallbladder and protect liver, invigorate spleen and calm heart, thereby achieving the effects of delaying senility, improving immunity and improving the physiological condition of organisms. In addition, the intestine-benefiting life-prolonging oral liquid is low in cost, free of toxic and side effects and capable of being widely popularized and used.
The above-described embodiments of the present application do not limit the scope of the present application.
Claims (6)
1. An intestine-benefiting and life-prolonging oral liquid is characterized by comprising effective components, auxiliary material components and a solvent, wherein the effective components comprise carboxymethyl chitosan, β -cyclodextrin, fructo-oligosaccharide and stachyose, the auxiliary material components comprise white paeony root, bitter orange, radix rehmanniae, cassia occidentalis, poria cocos and radish seed, and the solvent is water.
2. The intestine-benefiting and life-prolonging oral liquid according to claim 1, wherein the mass ratio of the carboxymethyl chitosan, the β -cyclodextrin, the fructo-oligosaccharide and the stachyose is 1:1:2:1, and the mass ratio of the white paeony root, the bitter orange, the radix rehmanniae, the cassia occidentalis, the poria cocos and the radish seed is 1:1: 1.5: 1.5: 1.5: 2.
3. The intestine-benefiting and life-prolonging oral liquid as claimed in claim 2, wherein the effective components comprise, by weight, 5g of carboxymethyl chitosan, 5g of β -cyclodextrin, 10g of fructo-oligosaccharide and 5g of stachyose, and the auxiliary materials comprise, by weight, 5g of radix paeoniae alba, 5g of fructus aurantii, 7.5g of radix rehmanniae, 7.5g of semen cassiae torae, 7.5g of poria cocos and 10g of semen raphani.
4. The oral liquid for benefiting intestine and longevity according to claim 3, wherein the amount of the solvent is 200-300 ml.
5. A method for preparing the oral liquid for benefiting intestine and prolonging life as claimed in any one of the above claims 1-4, which comprises the steps of crushing and mixing auxiliary materials, preparing liquid medicine, introducing effective components, controlling viscosity and sterilizing,
wherein, the auxiliary material is smashed and is specifically included with the mixing process: pulverizing radix Paeoniae alba, fructus Aurantii, radix rehmanniae, semen Cassiae, Poria and Raphani semen, and mixing in a mixer to obtain mixed adjuvants;
the liquid medicine preparation process specifically comprises the following steps: adding appropriate amount of water into the mixed adjuvants, decocting at 80-95 deg.C for about 1 hr, filtering to remove residue, and collecting the upper layer medicinal liquid;
the step of introducing effective components comprises adding carboxymethyl chitosan, β -cyclodextrin, fructo-oligosaccharide and stachyose into the obtained medicinal liquid, stirring thoroughly until the effective components are dissolved in the medicinal liquid, and making into oral stock solution;
the viscosity control process specifically comprises the following steps: adjusting the viscosity of the oral stock solution to obtain oral liquid;
the sterilization process specifically comprises the following steps: sterilizing the oral liquid, wherein the sterilization time is 10-30 minutes, the sterilization temperature is 110-130 ℃, and the sterilization pressure is 1.0-1.2 kpa.
6. Use of an oral liquid according to any of claims 1 to 4, wherein the oral liquid is used as a beneficial additive in dairy products or health products for the middle-aged and elderly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010187906.4A CN111437248A (en) | 2020-03-17 | 2020-03-17 | Intestine-benefiting life-prolonging oral liquid and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010187906.4A CN111437248A (en) | 2020-03-17 | 2020-03-17 | Intestine-benefiting life-prolonging oral liquid and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111437248A true CN111437248A (en) | 2020-07-24 |
Family
ID=71629280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010187906.4A Pending CN111437248A (en) | 2020-03-17 | 2020-03-17 | Intestine-benefiting life-prolonging oral liquid and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111437248A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4451457A (en) * | 1981-02-18 | 1984-05-29 | Kureha Kagaku Kogyo Kabushiki Kaisha | Cyclodextrin and method for promoting the proliferation of intestinal bifidobacteria |
| CN104435666A (en) * | 2014-11-05 | 2015-03-25 | 北京润康普瑞生物技术有限公司 | Traditional Chinese medicine composition with effect of relaxing bowels, as well as preparation method and application thereof |
| CN110101711A (en) * | 2019-04-18 | 2019-08-09 | 东华理工大学 | A kind of removing toxic substances medicament and its application |
-
2020
- 2020-03-17 CN CN202010187906.4A patent/CN111437248A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4451457A (en) * | 1981-02-18 | 1984-05-29 | Kureha Kagaku Kogyo Kabushiki Kaisha | Cyclodextrin and method for promoting the proliferation of intestinal bifidobacteria |
| CN104435666A (en) * | 2014-11-05 | 2015-03-25 | 北京润康普瑞生物技术有限公司 | Traditional Chinese medicine composition with effect of relaxing bowels, as well as preparation method and application thereof |
| CN110101711A (en) * | 2019-04-18 | 2019-08-09 | 东华理工大学 | A kind of removing toxic substances medicament and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103124559B (en) | For the device of the compositionss and its preparation and application and delivering said composition of faecal microbiota implantation | |
| CN104829738B (en) | Application of sargassum graminifolium polysaccharide extract in improvement of intestinal flora and prevention and treatment of diabetes | |
| CN101214311B (en) | Compound scutellaria injection for treating fowls and domestic animals infectious disease and preparation thereof | |
| CN1223865A (en) | Live triple bifidobacteria preparation and preparing method thereof | |
| CN106490360A (en) | One boar green feed additive and preparation method thereof | |
| CN104436142B (en) | A kind of Chinese medicine composition for treating pig epidemic diarrhea | |
| WO2018188525A1 (en) | Composition for use in improving circulation in body and delaying aging as well as use thereof | |
| CN105535580A (en) | A biological agent for improving human body intestinal floras and a preparing method thereof | |
| CN102847017A (en) | Oral solution for prevention and treatment of piglet diarrhea, and preparation method thereof | |
| CN114191464A (en) | Traditional Chinese medicine microecological preparation for improving growth performance of ducks and application | |
| CN110172106A (en) | A kind of peach gum polysaccharide iron and its application | |
| CN113575964A (en) | Antioxidant and anti-aging probiotic composition and preparation method thereof | |
| CN101332256A (en) | Traditional Chinese medicine composition for infectious bursal disease and preparation method thereof | |
| CN105995443B (en) | Infant intestine-benefiting nutritional rice flour and preparation method thereof | |
| CN116855413A (en) | Bioactive substance for regulating human body microecological balance prepared from lactobacillus rhamnosus YSs069 and application thereof | |
| CN111437248A (en) | Intestine-benefiting life-prolonging oral liquid and preparation method and application thereof | |
| CN105641081A (en) | Traditional Chinese medicine oral liquid for treating sow endometritis | |
| CN110192653A (en) | A kind of preparation method of pregnant and lying-in women and children special-purpose probiotics | |
| CN103071148B (en) | Compound thymosin Alpha 1 injection for improving livability of piglet and preparation method | |
| CN107648284A (en) | Purposes of the hedgehog fungus extract in the preparation for preparing treatment and/or prevention intestinal bacilli illness relevant disease | |
| CN107411014A (en) | A kind of antifatigue milk piece | |
| CN102488767B (en) | Compound composition for treating bacterial diarrhoea of livestock and poultry | |
| CN105233250A (en) | Composite biological agent used for treating encephalopathy | |
| CN101780199B (en) | Traditional Chinese medicine breast perfusate for treating mastitis of dairy cattle and preparation method thereof | |
| CN104352582A (en) | Medicine for preventing and treating colibacillosis of chickens and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200724 |
|
| WD01 | Invention patent application deemed withdrawn after publication |